乙醇硬化治疗子宫内膜瘤:8年经验的安全性评估
该回顾性观察队列研究纳入2013年11月至2021年6月间126例子宫内膜瘤患者,共157次经阴道乙醇硬化治疗,分析并发症。治疗失败率为10.8%(17/157),并发症发生率为9.5%(15/157),其中I级7.1%、II级0.8%、III级1.6%、IV级0.8%,无V级并发症。作者认为该法可靠、微创,但存在需识别和预防的特定潜在危及生命的并发症。
要点
- 经阴道乙醇硬化治疗子宫内膜瘤的并发症发生率为9.5%(15/157),失败率为10.8%(17/157)。
- 多数并发症为Clavien-Dindo I级(7.1%),IV级乙醇中毒罕见(0.8%)但危及生命。
- 作者认为该法可作为腹腔镜手术的有效替代,但需规范操作以预防乙醇泄漏和中毒。
核心结论
- 经阴道乙醇硬化治疗是可靠、微创、可在门诊进行的方法,但存在需识别和预防的特定潜在危及生命的并发症。
- 作者认为该法是腹腔镜手术治疗子宫内膜瘤的有效替代方案,可限制卵巢储备的改变。
- 大多数并发症为Clavien-Dindo ≤IV级,预防措施或早期诊断治疗可容易实施。
研究设计与样本
- 回顾性观察队列研究,在学术医院开展,纳入2013年11月至2021年6月间126名年龄31.9±5.5岁(均值±标准差)的女性。
- 共分析157次乙醇硬化治疗(EST),由131次EST操作完成;纳入标准为至少一个大于10 mm的子宫内膜瘤,孤立或合并其他子宫内膜异位病灶,需因疼痛或不孕在辅助生殖治疗前接受治疗。
- 标准化操作:全麻下超声引导经阴道穿刺一个或多个子宫内膜瘤,完全抽出囊液并用生理盐水冲洗,注入96%乙醇至初始体积的60%,在囊内保留10分钟后完全抽出。
主要发现
- 治疗失败:157次EST中17次(10.8%),131次EST操作中14次(10.7%),126名女性中13名(10.3%)。
- 并发症:157次EST中15次(9.5%),131次EST操作中13次(9.9%),126名女性中13名(10.3%)。
- 126名女性中9名(7.1%)发生I级并发症,1名(0.8%)发生II级并发症(疑似盆腔感染接受药物治疗),2名(1.6%)发生III级并发症(卵巢脓肿),1名(0.8%)发生IV级并发症(乙醇中毒),未观察到V级并发症。
关键数值与推荐
- 治疗失败定义:因消化道间置、既往治疗子宫内膜瘤中乙醇丢失、无法抽吸子宫内膜异位液、生理盐水泄漏导致不能开始乙醇注射、或超声怀疑乙醇泄漏导致不能继续注射而禁忌穿刺。
- 术中并发症定义:乙醇丢失、血酒精浓度阳性、乙醇中毒;术后并发症定义:发热、生物学炎症综合征、卵巢脓肿。
- 并发症按Clavien-Dindo手术分类系统分为五个严重程度递增的等级。
临床怎么用
- 经阴道乙醇硬化治疗可在门诊基础上用于子宫内膜瘤管理,但需规范实施和推广操作流程以预防乙醇泄漏和中毒。
- 作者认为该法可限制卵巢储备的改变,可作为腹腔镜手术的有效替代。
- 对多数Clavien-Dindo ≤IV级并发症,可实施预防措施或至少早期诊断和治疗。
局限性
- 本研究为回顾性研究,未考虑疼痛评估。
- 未评估子宫内膜瘤经阴道乙醇硬化治疗的获益-风险平衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What are the complications of transvaginal ethanol sclerotherapy for the treatment of endometriomas? SUMMARY ANSWER: Sclerotherapy is a reliable, minimally invasive method applicable in outpatient procedures but with specific and potential life-threatening complications that need to be identified and prevented. WHAT IS KNOWN ALREADY: There are currently few data on the use of transvaginal ethanol sclerotherapy, and we mainly note septic complications. STUDY DESIGN, SIZE, DURATION: A retrospective observational cohort study was carried out. The study was conducted at an academic hospital and included 126 women aged 31.9 ± 5.5 years (mean ± SD), between November 2013 and June 2021. We analyzed a total of 157 ethanol sclerotherapy treatment (EST), treated by 131 EST procedures, in 126 women. PARTICIPANTS/MATERIALS, SETTING, METHODS: The study included women with an indication for transvaginal ethanol sclerotherapy. Indications were women with at least one endometrioma over 10 mm, isolated or associated with other endometriosis locations, requiring treatment for pain or infertility before assisted reproductive treatment. We followed a standardized transvaginal ethanol sclerotherapy procedure consisting of an ultrasound-guided transvaginal puncture of one or more endometriomas under general anesthesia. The cyst content was completely removed and flushed with saline solution. Ethanol (96%) was injected at 60% of the initial volume of the endometrioma, remained in the cyst for 10 min and was then completely removed. Ethanol loss was defined as a loss of 5 ml or more than 10% of the initial volume of the injected ethanol. Failure was defined by the contraindication of endometrioma puncture because of interposition of the digestive tract, ethanol loss in the previous endometrioma treated (in case of multiple ESTs), failure to aspirate the endometriotic fluid, contraindication to start ethanol injection owing to saline solution leakage, or contraindication to continue ethanol injection owing to suspicions of ethanol leakage at sonography. Intraoperative complications were defined by ethanol loss, positive blood alcohol level, and ethanol intoxication. Postoperative complications were defined by fever, biological inflammatory syndrome, and ovarian abscess. Complications were classified according to the Clavien and Dindo surgical classification, which is a system for classifying postoperative complications in five grades of increasing severity. MAIN RESULTS AND THE ROLE OF CHANCE: We reported a total of 17/157 (10.8%) transvaginal ethanol sclerotherapy failures during 14/131 (10.7%) transvaginal ethanol sclerotherapy procedures in 13/126 (10.3%) women. In the same sets of data, complication was reported for 15/157 (9.5%) transvaginal ethanol sclerotherapy in 13/131 (9.9%) transvaginal ethanol sclerotherapy procedures in 13/126 (10.3%) women. Nine of 126 women (7.1%) had a grade I complication, one (0.8%) had a grade II complication (medical treatment for suspicion of pelvic infection), two (1.6%) had a grade III complication (ovarian abscess) and one (0.8%) had a grade IV complication (ethanol intoxication). We did not observe any grade V complications. LIMITATIONS, REASONS FOR CAUTION: This was a retrospective study and pain assessment not considered. The benefit-risk balance of endometrioma transvaginal ethanol sclerotherapy was not evaluated. WIDER IMPLICATIONS OF THE FINDINGS: Our study is the first to evaluate the complications of transvaginal ethanol sclerotherapy with such a large cohort of women in a standardized protocol. Transvaginal ethanol sclerotherapy seems to be an effective alternative to laparoscopic surgery in the management of endometriomas and limits the alteration of ovarian reserve. Transvaginal ethanol sclerotherapy is a reliable, minimally invasive method applicable on an outpatient basis. The majority of complications are Clavien-Dindo ≤IV, for which preventative measures, or at least early diagnosis and treatment, can be easily performed. The risk of ethanol intoxication is rare, but it is a life-threatening risk that must be avoided by appropriate implementation and promotion of the sclerotherapy procedures. STUDY FUNDING/COMPETING INTEREST(S): None. TRIAL REGISTRATION NUMBER: Aix Marseille University's ethics committee registration number 2021-06-03-01.
引用
- Miquel L, Liotta J, Pivano A, et al. Ethanol endometrioma sclerotherapy: safety through 8 years of experience. Hum Reprod. 2024. PMID: 38327007. doi:10.1093/humrep/deae014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。